A preliminary study on occurrence of immune-related adverse events and its relationship to camrelizumab efficacy in treatment for non-small cell lung cancer
10.3760/cma.j.cn114015-20230912-00678
- VernacularTitle:卡瑞利珠单抗治疗非小细胞肺癌免疫相关不良事件发生情况及其与疗效关系的初步研究
- Author:
Shaojun WANG
1
;
Chao LI
;
Caixia LIU
;
Wuyun SU
;
Congxiu HUANG
Author Information
1. 内蒙古医科大学附属医院肿瘤内科，呼和浩特 010050
- Publication Type:Journal Article
- Keywords:
Carcinoma, non-small cell lung;
Immune checkpoint inhibitors;
Antineoplastic agents;
Drug-related side effects and adverse reactions;
Camrelizumab
- From:
Adverse Drug Reactions Journal
2024;26(1):12-17
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the occurrence of immune-related adverse events (irAEs) and the relationship to efficacy of camrelizumab in treatment for patients with non-small cell lung cancer (NSCLC).Methods:Clinical data of patients with NSCLC who received camrelizumab in at the Affiliated Hospital of Inner Mongolia Medical University from December 2020 to December 2022 were collected, and the efficacy of camrelizumab and the occurrence of irAEs were retrospectively analyzed. Patients were divided into irAEs group and non-irAEs group according to whether they developed irAEs. The objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) of the 2 groups were compared.Results:A total of 48 patients were entered in the analysis, including 41 males (85.4%) and 7 females (14.6%), with an age of (65.9±7.4) years; the median treatment cycle was 9 (6, 14); the overall ORR was 52.1% (25/48), the DCR was 83.3% (40/48), and the median PFS was 11 months. Among the 48 patients, 34 patients (70.8%) had 59 times of irAEs, of which 8 patients (16.7%) had at least one irAE of grade ≥3. The median time of irAEs occurrence was 5 (3, 7) treatment cycles. The irAEs with an incidence of >10% included reactive cutaneous capillary endothelial proliferation (RCCEP), thyroid injury, skin injury, lung injury, liver injury, and blood toxicity, with the incidences of 37.5% (18/48), 18.8 (9/48), 16.7% (8/48), 12.5% (6/48), 10.4% (5/48), and 10.4% (5/48), respectively. Compared with non-irAEs group, patients in the irAEs group had higher ORR and DCR [64.7% (22/34) vs. 3/14, 91.2% (31/34) vs. 9/14] and longer median PFS (12.0 months vs. 7.0 months, hazard ratio=0.418, 95% confidence interval: 0.193-0.905), and the differences were statistically significant (all P<0.05). Conclusions:The common irAEs of camrelizumab in treatment for patients with NSCLC was RCCEP, and fewer serious irAEs occurs. To a certain extent, patients who experience irAEs during camrelizumab treatment may predict a more pronounced therapeutic response.
